This clinical trial is focused on studying treatments for advanced melanoma, a type of skin cancer that has spread to other parts of the body. The study will explore the effectiveness of a medication called tebentafusp, both on its own and in combination with another medication called pembrolizumab (also known as Keytruda). Participants in the study will have previously received treatment for their melanoma. The purpose of the study is to see if these treatments can help reduce the cancer and improve survival rates compared to other treatments chosen by the doctors involved in the study.
During the study, participants will receive either the tebentafusp regimen or a treatment selected by their doctor, which may include medications like diphenhydramine, dexamethasone, or paracetamol. Tebentafusp and pembrolizumab are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.
The study aims to determine if the tebentafusp regimen can lead to a greater reduction in cancer markers and improve overall survival compared to the other treatments. Participants will be monitored for any side effects and changes in their health throughout the study. The results will help researchers understand the potential benefits of tebentafusp for people with advanced melanoma and guide future treatment options.
Austria 
Belgium 
France 
Germany 
Italy 
Poland 
Spain 
